Hyperbaric Oxygenotherapy in Treatment of Children with Neuroblastoma of Highest Risk: Experience in 1997–2000

Česká verzia

Authors: P. Došel ¹; M. Sázel ¹; J. Staňková ²; P. Kavan ²; H. Křížová ²; P. Gajdoš ³
Authors place of work: Ústav leteckého zdravotnictví Praha, ředitel MUDr. Dušan Bartoš, CSc. ¹; Klinika dětské onkologie FN Motol a 2. LF UK v Praze, přednosta Prof. MUDr. Jan Starý, DrSc. ²; Klinika nukleární medicíny FN Motol a 2. LF UK v Praze, přednosta Doc. MUDr. Petr Vlček, CSc. ³
Published in the journal: Pracov. Lék., 59, 2007, No. 1-2, s. 5-8.
Category: Original Papers

Summary

Treatment of highest risk neuroblastoma is problematic. 5 years overall survival is about 20%. Prognosis can be improved by administration of 131I MIBG. The advantage of this targeted tumour specific radiotherapy is the possibility of achievement 5–10 fold higher dose in comparison with external irradiation with less organ toxicity. 14 131I MIBG treatment applications were done in 7 patients with highest risk neuroblastoma in this period. Four children were given one administration, three children were given repetitive administrations. Out of these seven patients, three survived longer. 5.5 GBq was given within the first administration, 3.7 GBq in subsequent courses, irrespective of body weight, always followed by four days 100 minutes lasting hyperbaric oxygen therapy. Immediate tolerance of treatment was good. 131I MIBG treatment is well tolerated targeted irradiation enhanced by hyperbaric oxygen therapy.

Key words:
neuroblastoma, MIBG, hyperbaric oxygen therapy

Zdroje

1. VOUTE, P. A., KRAKER DE, J., HOEFNAGEL, C. A. Tumours of the Sympathetic Nervous System: Neuroblastoma, Ganglioneuroma and Phacochromocytoma. In Cancer in Children. Clinical Management. 3rd edition. Eds. P. A. Voute, A. Barrett, J. Lemerle. Heidelberg : Spinger Verlag 1992.

2. BRODCUR, G. M., PRITCHARD, J., BERTOLD, F., CARLSEN, N. L., CASTEL, V. CASTLEBERRY, R. P. et al. Revisions of international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol., 1993, 11, s. 1466–1477.

3. GRAY, L. H., CONGER, A. D., EBERT, M., HORNSEY S., SCOTT O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. B. J. Radiol., 1953, 26, s. 638–648.

4. FUJIMURA, F. Experimental studies on radiations effects under high oxygen pressure. J. Osaka Dent. Univ., 1974, 19, s. 100–108.

5. HENK, J. H., SMITH, C., W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Lancet, 1977, 2, 4, s.105.

6. NIAS, A., H., W. The oxygen problem in radiotherapy. In Colin, B. Seymour, Carmel, Mothersill (eds.) New Developments in Fundamental and Applied Radiobiology. Taylor & Francis Ltd. 4 Fohn St. London WCIN 2ET, 1991 s. 318–327.